Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com

Chemistry and Pharma Blogs:
Pharmalot
Org Prep Daily
On Pharma
One in Ten Thousand
Away From the Bench
QDIS Blog
Chemical Musings
In Vivo Blog
The Chemblog
Molecule of the Day
Kinase Pro
Drugs and Poisons
Jungfreudlich
Chembark
Social Detritus
Pharmagossip
Whistling in the Wind
Organometallic Current
Great Molecular Crapshoot
Post Doc Ergo Propter Doc
A Chemist's Lab Notebook
The Curious Wavefunction Totally Synthetic
Pharma's Cutting Edge
The F- Blog
Synthetic Environment
Atom Pusher
Chemistry World Blog
Carbon-Based Curiosities
Eye on FDA
Hdreioplus
Closeted Chemistry
Chemical Forums
Curly Arrow
Power of Goo
Carbon Tet
Totally Medicinal
Sceptical Chymist
Lamentations on Chemistry
PeterMR
Mining Drugs
Regulatory Affairs of the Heart
Making Graphite Work
Liquid Carbon
Half-Decent Pharma Blog


Science Blogs and News:
The Loom
Uncertain Principles
The Crimson Canary
Fierce Biotech
Blogs for Industry
The Futile Cycle
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
TP With Page Numbers
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
Oncology Updates
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Daily Biomed
Voyage to Arcturus
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
The Mass Spectrometry Blog
Nodal Point
Slashdot Science
A Scientist's Life
Living the Scientific Life
John Johnson
Humans in Science
Tobias Sing's Bioinformatics Blog
Speculist
Science, Shrimp and Grits
Biopeer
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
MedPundit
Med Tech Sentinel
DB's Medical Rants
Dr. Charles
RangelMD
GruntDoc
The Health Care Blog
Cut to Cure
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Asymmetrical Information
Belmont Club
Man Without Qualities
Belgravia Dispatch
Mickey Kaus
Colby Cosh
Progressive Reaction
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
Just Released the 2008 Tribalization of Business study - an in-depth look at how 140+ organizations are managing and measuring online communities

In the Pipeline

« COX-2 Aftermath | Main | An Antiviral Example »

February 21, 2005

Can Med-Chem Help With Bird Flu?

Email This Entry

Posted by Derek

If avian flu does gain a foothold in humans, what can drug companies do about it? (This should give you the latest headlines on the disease.) It's definitely something to worry about. There hasn't been a real rampager of a flu epidemic in a long time, and a pessimist would say that we're overdue.

The answer to my question is "Work on a vaccine!" Because if you rephrase it and ask "What can people like this Derek Lowe guy and his hotshot medicinal chemistry buddies do?", the answer is "Not much." It's not a widely appreciated fact among the public, but we have hardly any drugs that affect viral diseases. The disease with by far the largest number of therapeutic options is HIV infection, and if you find that an unnerving thought, you should.

The problem, as I've mentioned before, is that viruses don't give you much to work with. They have very small genomes, and thus code for a bare-bones set of proteins. Since those are generally what we'd attack, we're often at a loss to find a good drug target. Sometimes you can find a target in the human cells that the virus attacks, but that takes a lot of basic research into the infection process.

And even if we find a target, we're years away from a drug. Getting a chemical lead structure, optimizing it, making sure that it actually does some good (and doesn't do a corresponding amount of harm!) - it's a terribly slow process. And it's remained that way despite hundreds of millions of dollars waiting to be picked up off the ground by the first company that can shorten it. The incentives are there; the technology isn't.

That time scale probably won't be much use if we get into an epidemic one of these years. The virus will outrun us. The best thing we can be doing now is learning everything we can about the whole class of H5N1 influenza viruses and how to make broadly active vaccines against them and their combinations with human agents. Prevention, monitoring, and immunology are going to have to save us if we get into trouble. Because though it pains me to say it, people like me aren't going to be able to help.

Comments (7) + TrackBacks (0) | Category: Infectious Diseases


COMMENTS

1. David Govett on February 21, 2005 9:32 PM writes...

Unless you are able to eliminate 100% of the avian virus in a population, you'll be playing their game and will only improve their resistance. As they say, all or nothing at all.

Permalink to Comment

2. Kay on February 22, 2005 12:06 PM writes...

What about lack of commercial appeal? As we know, there are lots of (infectious) deseases that have the need, but marketing/business types in pharma kill the will.

Permalink to Comment

3. Amante on February 22, 2005 4:29 PM writes...

Vaccines generally aren't a huge commercial draw, you are right, however that isn't all of the problem. We are hurt from the start by the formidable opponent that a virus is and by the difficulty of storing vaccines in the case of a huge outbreak. Most companies keep little or no reserves because of how easily these things breakdown.

Permalink to Comment

4. Katherine on February 23, 2005 1:49 PM writes...

Are the current flu antivirals likely to be helpful in an avian flu epidemic?

Permalink to Comment

5. Kokostrollet on March 19, 2005 2:12 PM writes...

What is your opinion on how much (potential) protection a drug such as Tamiflu would give you vs. avian flu? None at all?

Permalink to Comment

6. Fen on March 23, 2005 11:59 PM writes...

Late to the party, but just one question:

Assuming a Biological attack, like a SuperFlu, whats the turn-around time for a vaccine from CDC? Weeks? Months?

I seem to recall that earlier efforts were not hindered by vectoring from modern/international transportation systems.

Permalink to Comment

7. Paul Dietz on March 24, 2005 1:38 PM writes...

I've stockpiled a course of tamiflu in the freezer, in case a pandemic does break out. If that happens, the drug will be nearly impossible to get, since demand will far outstrip the production capacity.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Pfizer's Prospects: Just Ducky
Happy Fourth of July
I Can Has Ugly Molecules?
More Pfizer Layoffs?
Leaving Comments: A Fix
The Gates Foundation: Dissatisfied With Results?
Another Alzheimer's Compound Goes Down
Unknown - But You Can Buy It